What are the clinical presentation, diagnostic tests, and management options for leishmaniasis?

Leishmaniasis: Clinical Presentation, Diagnostic Tests, and Management

Leishmaniasis presents in three main clinical syndromes—cutaneous (CL), mucosal (ML), and visceral (VL)—each requiring distinct diagnostic and treatment approaches based on the infecting species and geographic acquisition. 1

Clinical Presentation

Cutaneous Leishmaniasis (CL)

• Most common form worldwide, particularly in North America among travelers and immigrants from endemic areas 1
• Lesions develop at sandfly bite sites, appearing as papules that slowly enlarge and typically ulcerate after weeks to months
• May present as persistently nodular forms without ulceration
• Natural history involves slow spontaneous healing as cell-mediated immunity develops 1
• Complex CL features requiring systemic therapy include: 2
  • Lesions caused by Viannia species (increased ML risk)
  • ≥4 lesions of substantial size (>1 cm)
  • Large individual lesions (≥5 cm diameter)
  • Facial, joint, or genital involvement
  • Regional adenopathy or subcutaneous nodules
  • Immunocompromised host

Mucosal Leishmaniasis (ML)

• Develops in a minority of patients infected with L. (V.) braziliensis and related Viannia species, particularly from South America 1
• Can occur after CL healing or concomitantly with cutaneous lesions
• Presents with destructive naso-oropharyngeal/laryngeal lesions
• Symptoms include dysphonia (79%), dysphagia (17%), with mean diagnostic delay of 18.4 months 3
• Progressive tissue destruction including nasal septum perforation 2

Visceral Leishmaniasis (VL)

• Potentially life-threatening and requires prompt treatment 1
• Amastigotes disseminate throughout the reticuloendothelial system
• Clinical signs include fever, hepatosplenomegaly, pancytopenia, weight loss
• Fever typically abates within 1 week of effective treatment 1
• Organomegaly resolves over 3-6 months 1
• Post-kala-azar dermal leishmaniasis (PKDL) can develop in 10-27.5% of Indian cases and 1.5-60% in Sudan 1

Diagnostic Tests

For Cutaneous Leishmaniasis

Use multiple diagnostic approaches simultaneously to maximize detection: 1

1. Molecular testing (PCR/qPCR) - Most sensitive available test

   • Sensitivity: 89-100%, Specificity: 57-100% depending on target gene 4
   • Should be performed routinely 1

2. Tissue collection - Aspirates or biopsy specimens for: 1

   • Microscopy (smears showing amastigotes)
   • Histopathology (Giemsa stain highlights amastigotes) 5
   • Culture (allows species identification)
   • Molecular testing

3. Species identification - Critical for management decisions

   • Determines ML risk and treatment selection 1
   • Performed by reference laboratories using DNA-based assays or isoenzyme analysis

4. Serology NOT recommended for CL diagnosis - neither sensitive nor specific 1

For Visceral Leishmaniasis

Preferred diagnostic sequence: 2

1. Bone marrow aspiration - First-line tissue source

   • Alternative sources: liver, enlarged lymph nodes, whole blood (buffy coat)
   • For microscopy, culture, and molecular testing 2

2. Serological testing - Recommended when definitive tests unavailable or negative 1

   • rK39-based rapid diagnostic tests: Sensitivity 78-96.4%, Specificity 93-97% 4
   • Direct agglutination test: Sensitivity 97.3-99.1%, Specificity 97.5-98.8% 4
   • Caveat: May be negative in HIV/AIDS or immunocompromised patients 1
   • Cannot assess treatment response—antibodies persist for years 1

3. Molecular testing - Highest sensitivity, especially in immunocompromised patients 2

4. In immunocompromised patients: Collect blood for buffy coat examination, culture, and molecular analyses 2

Diagnostic Performance Summary

• Microscopy: Lower sensitivity (32.8-80.8% for CL, 44-67% for VL) but high specificity (>95%) 4
• Loop-mediated isothermal amplification: Sensitivity 89.7-95%, Specificity 63.6-100% 4
• Molecular diagnostics superior but underutilized in resource-limited settings 4

Management

Cutaneous Leishmaniasis Treatment Algorithm

Decision pathway based on complexity: 1, 2

Simple CL (local therapy appropriate):

• Topical paromomycin - First-line for most lesions

  • Use for up to 10 lesions, including those >4 cm 6
  • Contraindication: Proximity to mucosal areas 6

• Cryotherapy ± intralesional meglumine antimoniate - For localized Old World CL without mucosal risk 6

Complex CL (systemic therapy required):

• Pentamidine (IV/IM) - Particularly useful for L. guyanensis infections, multiple lesions, or remote settings 6

• Liposomal amphotericin B (L-AmB) - Consider for:

  • Treatment failures
  • L. infantum in immunosuppressed patients
  • Mucosal or rapidly evolving South American lesions 6

• Miltefosine - When hospitalization impossible (note teratogenicity) 6

• Pentavalent antimonials - 20 mg SbV/kg/day IV or IM for 28 days

  • Avoid in regions with high resistance (e.g., Amazonian Bolivia, southeastern Peru) 1

Mucosal Leishmaniasis Treatment

All ML cases require systemic therapy 1

• Same agents as complex CL
• Liposomal amphotericin B preferred for severe cases
• Requires otolaryngology consultation for biopsy and assessment 2

Visceral Leishmaniasis Treatment

Immunocompetent Patients:

First-line: Liposomal amphotericin B (L-AmB) 2

• FDA-approved regimen: 3 mg/kg/day IV on days 1-5,14, and 21 (total 21 mg/kg)
• East African VL: May require 40 mg/kg or more 2
• Highest cure rates achieved 4

Alternative for South Asian L. donovani (age ≥12 years, weight ≥30 kg, not pregnant/breastfeeding):

• Miltefosine: 2.5 mg/kg/day (max 150 mg in 3 divided doses) for 28 days 2
• Particularly effective in patients <75 kg 2

Pentavalent antimonials: 20 mg SbV/kg/day IV or IM for 28 days

• Only in areas with <10% resistance 2
• Efficacy >90-95% in East Africa, Brazil, Greece 1

Immunocompromised Patients (including HIV/AIDS):

L-AmB at higher dosing 1

• 4 mg/kg/day IV on days 1-5,10,17,24,31,38 (total 40 mg/kg over 38 days)
• Combination therapy (e.g., L-AmB + miltefosine) for refractory cases 1
• Initiate or optimize antiretroviral therapy during or soon after VL treatment 1

Treatment Monitoring

Cutaneous Leishmaniasis:

• Monitor lesions for 6-12 months after treatment 2
• Expected response by 4-6 weeks: >50% size reduction, reepithelializing ulcers, no new lesions 2
• Complete healing: Typically by 3 months 2
• Treatment failure indicators: New lesions, worsening existing lesions, incomplete healing by 3 months 2
• Paradoxical inflammatory response may occur in first 2-3 weeks—difficult to distinguish from failure 2

Visceral Leishmaniasis:

• Clinical parameters correlate well with parasitologic response 1
• Fever resolution: <1 week
• Organomegaly improvement: Detectable by 10 days, complete by 3-6 months
• Rising blood counts, increasing appetite/weight 1
• Repeat bone marrow aspiration NOT recommended if showing timely clinical response 1

Critical Pitfalls to Avoid

1. Do not rely on serology alone for CL diagnosis - neither sensitive nor specific 1

2. Do not use serology to monitor VL treatment response - antibodies persist for months to years 1

3. Do not miss mucosal involvement - All patients with Viannia species or South American exposure require thorough naso-oropharyngeal examination even without symptoms 2

4. Do not use amphotericin B deoxycholate instead of L-AmB - almost always more toxic 1

5. Do not delay treatment in symptomatic VL - potentially life-threatening 1, 2

6. Species identification is critical - determines ML risk and optimal treatment 1

7. Geographic acquisition matters - resistance patterns vary (e.g., antimonial resistance in parts of Bolivia and Peru) 1

8. Immunocompromised patients require higher L-AmB doses and consideration of combination therapy 1